What is the ACXP stock price forecast for 2026-2027?
The 3 Wall Street analysts covering Acurx Pharmaceuticals, Inc. have a median 12-month price target of $10, with estimates ranging from $10 to $31. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ACXP stock a buy right now?
Of the 3 analysts covering Acurx Pharmaceuticals, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Acurx Pharmaceuticals, Inc. 24 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ACXP?
As at 22 Aug 2026, Acurx Pharmaceuticals, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
Will ACXP stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +575.7% from the last close, and Ticker Nerd's factor model ranks Acurx Pharmaceuticals, Inc. 24 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ACXP stock forecast for 2030?
No analyst covering Acurx Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACXP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $31 over the next 12 months.
How has ACXP stock performed over the past year?
Acurx Pharmaceuticals, Inc. returned -67.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Acurx Pharmaceuticals, Inc. do?
Acurx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing a new class of antibiotics targeting difficult-to-treat bacterial infections caused by Gram-positive priority pathogens identified by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration.
What is the latest news on ACXP?
The most recent item we track (PRNewsWire, 17 Aug 2026): "Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat". Acurx Pharmaceuticals announced that its proposed brand name, CIFBEZY, for its lead product candidate ibezapolstat received conditional acceptance from the FDA and federal trademark allowance from the USPTO. These initial milestones are intended to form the basis for the product's commercial identity as the company advances ibezapolstat toward its international Phase 3 registration program for both acute treatment and reduction of recurrence in C. difficile infection, with final FDA review of the name to be submitted at the time of the NDA marketing application.
